10/19/2011

Telavancin and vancomycin had similar cure rates, 72% and 73%, respectively, for skin and skin structure infections in obese patients, though the serious adverse event rate was higher in the telavancin group (11% compared with 3%), according to an analysis of two late-stage trials.

Full Story:
Dermatology News

Related Summaries